Protocol Ledger

NCT04776447 · Phase II · COMPLETED

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Interventional Phase II clinical trial protocol NCT04776447 sponsored by Fundación GECP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-16 Enrollment: 38 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04776447
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)38 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04776447
Protocol FieldVerified Registry Value
NCT IdentifierNCT04776447
Consolidated Lead SponsorFundación GECP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment38 participants (ACTUAL)
Registered Start Date2021-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04776447
Hospital Research SiteLocationSite Profile
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->
Hospital General Universitario de ElcheElche, SpainOpen Hospital Dossier ->
Hospital de La Santa Creu I Sant PauBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI